Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. The company called the ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. East Asian Americans are ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Tokyo, Jan. 30 (Jiji Press)--Japan's Takeda Pharmaceutical Co. said Thursday that its president and CEO, Christophe Weber, will step down at its general shareholders meeting in June 2026.

Japan's epigenetics market is evolving rapidly, with a strong emphasis on AI-driven research and personalized medicine, addressing complex diseases through innovative therapeutic approaches.New Delhi, ...

The global hypoparathyroidism treatment market is on the cusp of notable growth, according to a comprehensive analysis conducted by Future Market Insights. In 2022, the market was valued at USD 777.4 ...